Prostatype Genomics AB
Research Prostatype Genomics AB (PROGEN) on Bullrun: market cap SEK 27.82M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPROGEN
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencySEK
- Market capSEK 27.82M
- Financial periodFY2025
- RevenueSEK 594.00K
- Revenue growth198.5%
- Net income-SEK 44.50M
- Free cash flow-SEK 37.24M
- Gross margin100.0%
Valuation Snapshot
latest market cap is SEK 27.82M.
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision.
Frequently asked questions
What is Prostatype Genomics AB's market cap?
Prostatype Genomics AB's market capitalization is SEK 27.82M.
What does Prostatype Genomics AB do?
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System...